Compare OMI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMI | ACRS |
|---|---|---|
| Founded | 1882 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.2M | 230.8M |
| IPO Year | N/A | 2015 |
| Metric | OMI | ACRS |
|---|---|---|
| Price | $3.06 | $3.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $6.46 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,768,859,000.00 | $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.03 | N/A |
| 52 Week Low | $2.38 | $1.05 |
| 52 Week High | $15.54 | $3.57 |
| Indicator | OMI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 66.07 |
| Support Level | $2.38 | $3.12 |
| Resistance Level | $2.67 | $3.48 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 92.57 | 79.80 |
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.